8-K Announcements
6Material company update
Apr 14, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Feb 19, 2026·SEC
Praxis Precision Medicines, Inc.(PRAX)Earnings, Financials & Key Ratios
PRAX•NASDAQ
$333.30
$7.5B mkt cap·Price updated May 6, 2026
AboutPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$326M-63.2%
- Net Income-$303M-65.9%
- EPS (Diluted)-13.48-32.0%
- ROE-45.83%+35.4%
- ROIC-65.03%+51.8%
- Debt/Equity0.00-95.9%
PRAX Key Insights
Praxis Precision Medicines, Inc. (PRAX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Profits declining 37.4% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 25.7% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PRAX Price & Volume
Praxis Precision Medicines, Inc. (PRAX) stock price & volume — 10-year historical chart
Loading chart...
PRAX Growth Metrics
Praxis Precision Medicines, Inc. (PRAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-65.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-31.06%
Return on Capital
10 Years-100.4%
5 Years-96.38%
3 Years-97.27%
Last Year-49.29%
PRAX Recent Earnings
Praxis Precision Medicines, Inc. (PRAX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 2/12 qtrs (40%)
Q1 2026Latest
Feb 19, 2026EPS
$3.50
Est $3.13
-12.0%
Revenue
—
Est $66,667
Q4 2025
Nov 5, 2025EPS
$3.36
Est $3.45
+2.6%
Revenue
—
Est $256,090
Q3 2025
Aug 4, 2025EPS
$3.31
Est $3.40
+2.6%
Revenue
—
Est $59,440
Q2 2025
May 2, 2025EPS
$3.29
Est $3.20
-2.8%
Revenue
—
Est $198,800
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 19, 2026 | $3.50vs $3.13-12.0% | —vs $66,667 |
| Q4 2025 | Nov 5, 2025 | $3.36vs $3.45+2.6% | —vs $256,090 |
| Q3 2025 | Aug 4, 2025 | $3.31vs $3.40+2.6% | —vs $59,440 |
| Q2 2025 | May 2, 2025 | $3.29vs $3.20-2.8% | —vs $198,800 |
Based on last 12 quarters of dataView full earnings history →
PRAX Peer Comparison
Praxis Precision Medicines, Inc. (PRAX) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.78B | 22.35 | 16.43 | 31.85% | 24.94% | 28.47% | 4.16% | 0.07 |
 NRIX | 1.69B | 16.60 | -5.44 | 53.95% | -314.9% | -49.09% | 0.10 | |
 ARVN | 678.63M | 10.61 | -8.29 | -0.3% | -30.77% | -14.25% | 0.02 | |
 LGND | 4.57B | 232.30 | -1055.91 | 27.28% | 19.34% | 5.11% | 1.7% | 0.01 |
 OVID | 368.42M | 2.83 | -11.79 | 11.81% | -240.11% | -23.98% | 0.01 | |
 PTCT | 5.39B | 65.04 | 8.36 | 114.51% | 39.44% | 13.02% | ||
 KALA | 833.23K | 0.11 | -0.02 | -141.11% | -388.29% | 2.62 | ||
 ENOV | 1.38B | 24.12 | -1.16 | 6.66% | -52.69% | -79.39% | 1.44% | 0.06 |
Compare PRAX vs Peers
Praxis Precision Medicines, Inc. (PRAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRAX Income Statement
Praxis Precision Medicines, Inc. (PRAX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 2.45M | 8.55M | 0 |
| Revenue Growth % | - | - | - | - | - | - | 249.53% | -100% |
| Cost of Goods Sold | 1K | 679K | 0 | 0 | 154.44M | 86.77M | 152.41M | 140K |
| COGS % of Revenue | - | - | - | - | - | 3545.81% | 1781.98% | - |
| Gross Profit | -1K▲ 0% | -679K▼ 67800.0% | 0▲ 100.0% | 0▲ 0% | -154.44M▲ 0% | -84.32M▲ 45.4% | -143.86M▼ 70.6% | -140K▲ 99.9% |
| Gross Margin % | - | - | - | - | - | -3445.81% | -1681.98% | - |
| Gross Profit Growth % | - | -67800% | 100% | - | - | 45.4% | -70.61% | 99.9% |
| Operating Expenses | 22.72M | 35.79M | 61.97M | 167.33M | 60.55M | 42.05M | 56.3M | 326.06M |
| OpEx % of Revenue | - | - | - | - | - | 1718.59% | 658.31% | - |
| Selling, General & Admin | 3.9M | 6.23M | 16.99M | 47.08M | 59.55M | 42.05M | 56.3M | 59.08M |
| SG&A % of Revenue | - | - | - | - | - | 1718.59% | 658.31% | - |
| Research & Development | 18.82M | 29.56M | 44.98M | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M |
| R&D % of Revenue | - | - | - | - | - | 3545.81% | 1781.98% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -154.04M | -86.77M | -152.41M | 0 |
| Operating Income | -22.72M▲ 0% | -35.79M▼ 57.5% | -61.97M▼ 73.1% | -167.33M▼ 170.0% | -214.99M▼ 28.5% | -126.37M▲ 41.2% | -200.16M▼ 58.4% | -326.2M▼ 63.0% |
| Operating Margin % | - | - | - | - | - | -5164.41% | -2340.29% | - |
| Operating Income Growth % | - | -57.53% | -73.15% | -170.03% | -28.48% | 41.22% | -58.39% | -62.96% |
| EBITDA | -22.72M | -35.11M | -61.92M | -167.15M | -214.57M | -125.94M | -199.81M | -326.06M |
| EBITDA Margin % | - | - | - | - | - | -5146.75% | -2336.1% | - |
| EBITDA Growth % | - | -54.55% | -76.35% | -169.95% | -28.37% | 41.3% | -58.65% | -63.19% |
| D&A (Non-Cash Add-back) | 1K | 679K | 50K | 182K | 419K | 432K | 358K | 140K |
| EBIT | -26.27M | -35.6M | -61.97M | -167.33M | -213.99M | -126.37M | -200.16M | -303.27M |
| Net Interest Income | -35K | 193K | 140K | 0 | 0 | 0 | 17.35M | 22.93M |
| Interest Income | 92K | 193K | 140K | 0 | 0 | 0 | 17.35M | 22.93M |
| Interest Expense | 127K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -3.68M | 193K | 140K | 271K | 957K | 3.1M | 17.35M | 22.93M |
| Pretax Income | -26.4M▲ 0% | -35.6M▼ 34.8% | -61.83M▼ 73.7% | -167.06M▼ 170.2% | -214.03M▼ 28.1% | -123.28M▲ 42.4% | -182.82M▼ 48.3% | -303.27M▼ 65.9% |
| Pretax Margin % | - | - | - | - | - | -5037.88% | -2137.48% | - |
| Income Tax | 133K | -84K | -8K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.5% | 0.24% | 0.01% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -26.54M▲ 0% | -35.51M▼ 33.8% | -61.82M▼ 74.1% | -167.06M▼ 170.2% | -214.03M▼ 28.1% | -123.28M▲ 42.4% | -182.82M▼ 48.3% | -303.27M▼ 65.9% |
| Net Margin % | - | - | - | - | - | -5037.88% | -2137.48% | - |
| Net Income Growth % | - | -33.83% | -74.08% | -170.24% | -28.11% | 42.4% | -48.3% | -65.88% |
| Net Income (Continuing) | -26.54M | -35.51M | -61.82M | -167.06M | -214.03M | -123.28M | -182.82M | -303.27M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -306.73▲ 0% | -348.24▼ 13.5% | -103.61▲ 70.2% | -58.96▲ 43.1% | -69.33▼ 17.6% | -18.69▲ 73.0% | -10.21▲ 45.4% | -13.48▼ 32.0% |
| EPS Growth % | - | -13.53% | 70.25% | 43.09% | -17.59% | 73.04% | 45.37% | -32.03% |
| EPS (Basic) | -306.73 | -348.24 | -103.61 | -58.96 | -69.33 | -18.69 | -10.21 | -13.48 |
| Diluted Shares Outstanding | 86.51K | 101.97K | 596.68K | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
| Basic Shares Outstanding | 86.51K | 101.97K | 596.68K | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
PRAX Balance Sheet
Praxis Precision Medicines, Inc. (PRAX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 19.13M | 45.5M | 302.33M | 287.41M | 110.84M | 84.88M | 404.37M | 610.91M |
| Cash & Short-Term Investments | 17.95M | 44.81M | 296.61M | 275.91M | 100.49M | 81.3M | 392.57M | 599.33M |
| Cash Only | 17.95M | 44.81M | 296.61M | 138.7M | 61.62M | 81.3M | 215.37M | 357.33M |
| Short-Term Investments | 0 | 0 | 0 | 137.21M | 38.87M | 0 | 177.19M | 242M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 3.58M | 11.8M | 11.58M |
| Total Non-Current Assets | 703K | 2.2M | 851K | 5.34M | 4.29M | 3.07M | 78.74M | 327M |
| Property, Plant & Equipment | 103K | 1.58M | 836K | 4.87M | 3.87M | 2.65M | 1.36M | 239K |
| Fixed Asset Turnover | - | - | - | - | - | 0.92x | 6.28x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 600K | 0 | 0 | 0 | 0 | 0 | 76.96M | 0 |
| Other Non-Current Assets | 0 | 620K | 15K | 472K | 416K | 416K | 416K | 326.76M |
| Total Assets | 19.83M▲ 0% | 47.69M▲ 140.5% | 303.18M▲ 535.7% | 292.75M▼ 3.4% | 115.13M▼ 60.7% | 87.95M▼ 23.6% | 483.11M▲ 449.3% | 937.91M▲ 94.1% |
| Asset Turnover | - | - | - | - | - | 0.03x | 0.02x | - |
| Asset Growth % | - | 140.53% | 535.67% | -3.44% | -60.67% | -23.61% | 449.31% | 94.14% |
| Total Current Liabilities | 5.14M | 6.82M | 15.72M | 38.43M | 34.34M | 15.75M | 37.55M | 59.77M |
| Accounts Payable | 3.39M | 2.67M | 4.09M | 10.78M | 14.67M | 5.82M | 12.53M | 24.63M |
| Days Payables Outstanding | 1000K | 1.43K | - | - | 34.68 | 24.46 | 30 | 64.21K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 110K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 2.82M | 1.39M | 0 | 0 |
| Other Current Liabilities | 1.02M | 0 | 0 | 7.18M | 2.8M | 3.7M | 9.37M | 35.03M |
| Current Ratio | 3.72x | 6.67x | 19.23x | 7.48x | 3.23x | 5.39x | 10.77x | 10.22x |
| Quick Ratio | 3.72x | 6.67x | 19.23x | 7.48x | 3.23x | 5.39x | 10.77x | 10.22x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2K | 763K | 0 | 3.5M | 4.68M | 2.53M | 110K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 763K | 0 | 3.5M | 2.5M | 1.37M | 110K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 5.15M | 7.58M | 15.72M | 41.94M | 39.02M | 18.28M | 37.66M | 59.77M |
| Total Debt | 0 | 1.46M | 763K | 4.31M | 3.5M | 2.5M | 1.37M | 110K |
| Net Debt | -17.95M | -43.36M | -295.85M | -134.39M | -58.12M | -78.81M | -214M | -357.22M |
| Debt / Equity | - | 0.04x | 0.00x | 0.02x | 0.05x | 0.04x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -206.89x | - | - | - | - | - | - | - |
| Total Equity | 14.68M▲ 0% | 40.11M▲ 173.2% | 287.46M▲ 616.6% | 250.81M▼ 12.7% | 76.11M▼ 69.7% | 69.67M▼ 8.5% | 445.45M▲ 539.4% | 878.14M▲ 97.1% |
| Equity Growth % | - | 173.21% | 616.62% | -12.75% | -69.66% | -8.46% | 539.38% | 97.13% |
| Book Value per Share | 169.72 | 393.36 | 481.76 | 88.62 | 24.77 | 10.57 | 24.88 | 39.02 |
| Total Shareholders' Equity | 14.68M | 40.11M | 287.46M | 250.81M | 76.11M | 69.67M | 445.45M | 878.14M |
| Common Stock | 1K | 1K | 4K | 5K | 5K | 13K | 14K | 15K |
| Retained Earnings | -41.37M | -81.01M | -149.55M | -316.62M | -530.64M | -653.92M | -836.74M | -1.14B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1K | 0 | 0 | -176K | -173K | 0 | 654K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRAX Cash Flow Statement
Praxis Precision Medicines, Inc. (PRAX) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -20.72M | -32.79M | -52.62M | -124.55M | -185.04M | -111.14M | -131.76M | -249.07M |
| Operating CF Margin % | - | - | - | - | - | -4541.72% | -1540.48% | - |
| Operating CF Growth % | - | -58.23% | -60.5% | -136.69% | -48.56% | 39.94% | -18.55% | -89.04% |
| Net Income | -26.54M | -35.51M | -61.82M | -167.06M | -214.03M | -123.28M | -182.82M | -303.27M |
| Depreciation & Amortization | 1K | 679K | 50K | 182K | 419K | 432K | 358K | -3.45M |
| Stock-Based Compensation | 579K | 0 | 5.21M | 22.69M | 28.59M | 24.86M | 41.36M | 33.94M |
| Deferred Taxes | 3.65M | 0 | 0 | 2.09M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 127K | 668K | 696K | 1.41M | 1.75M | -121K | -1.58M | 1.03M |
| Working Capital Changes | 1.46M | 1.38M | 3.24M | 16.13M | -1.78M | -13.03M | 10.92M | 22.68M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.67M | -837K | 960K | 7.27M | 3.89M | -8.86M | 6.71M | 12.1M |
| Cash from Investing | -63K | -103K | 0 | -140.52M | 96.89M | 38.95M | -248.49M | -311.15M |
| Capital Expenditures | -63K | -103K | 0 | -1.05M | -444K | -50K | 0 | -56K |
| CapEx % of Revenue | - | - | - | - | - | 2.04% | - | - |
| Acquisitions | 0 | 0 | 0 | 139.47M | -97.33M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -139.47M | 97.33M | 0 | 0 | 0 |
| Cash from Financing | 37.8M | 59.76M | 304.42M | 107.59M | 10.46M | 91.87M | 514.32M | 702.17M |
| Debt Issued (Net) | 1M | -633K | 0 | -763K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 36.8M | 60.39M | 304.42M | 105.71M | 9.56M | 91.59M | 512M | 704.26M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -30M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 88K | 2.63M | 904K | 279K | 2.33M | -2.09M |
| Net Change in Cash | 17.02M▲ 0% | 26.86M▲ 57.8% | 251.79M▲ 837.3% | -157.49M▼ 162.5% | -77.69M▲ 50.7% | 19.68M▲ 125.3% | 134.07M▲ 581.1% | 141.96M▲ 5.9% |
| Free Cash Flow | -20.78M▲ 0% | -32.89M▼ 58.2% | -52.62M▼ 60.0% | -125.6M▼ 138.7% | -185.49M▼ 47.7% | -111.19M▲ 40.1% | -131.76M▼ 18.5% | -249.12M▼ 89.1% |
| FCF Margin % | - | - | - | - | - | -4543.77% | -1540.48% | - |
| FCF Growth % | - | -58.25% | -60% | -138.69% | -47.68% | 40.06% | -18.5% | -89.08% |
| FCF per Share | -240.25 | -322.53 | -88.19 | -44.38 | -60.36 | -16.86 | -7.36 | -11.07 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.92x | 0.85x | 0.75x | 0.86x | 0.90x | 0.72x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRAX Key Ratios
Praxis Precision Medicines, Inc. (PRAX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -180.73% | -129.62% | -37.74% | -62.07% | -130.94% | -169.13% | -70.98% | -45.83% |
| Return on Invested Capital (ROIC) | - | - | - | -232.34% | -239.92% | -2140.71% | -135.06% | -65.03% |
| Gross Margin | - | - | - | - | - | -3445.81% | -1681.98% | - |
| Net Margin | - | - | - | - | - | -5037.88% | -2137.48% | - |
| Debt / Equity | - | 0.04x | 0.00x | 0.02x | 0.05x | 0.04x | 0.00x | 0.00x |
| Interest Coverage | -206.89x | - | - | - | - | - | - | - |
| FCF Conversion | 0.78x | 0.92x | 0.85x | 0.75x | 0.86x | 0.90x | 0.72x | 0.82x |
| Revenue Growth | - | - | - | - | - | - | 249.53% | -100% |
PRAX SEC Filings & Documents
Praxis Precision Medicines, Inc. (PRAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
PRAX Frequently Asked Questions
Praxis Precision Medicines, Inc. (PRAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Praxis Precision Medicines, Inc. (PRAX) saw revenue decline by 100.0% over the past year.
Praxis Precision Medicines, Inc. (PRAX) reported a net loss of $303.3M for fiscal year 2025.
Dividend & Returns
Praxis Precision Medicines, Inc. (PRAX) has a return on equity (ROE) of -45.8%. Negative ROE indicates the company is unprofitable.
Praxis Precision Medicines, Inc. (PRAX) had negative free cash flow of $249.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More PRAX
Praxis Precision Medicines, Inc. (PRAX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates